NCT05476107View on ClinicalTrials.gov

SAD Study to Assess the Safety, Tolerability, PK, and In-Vivo Performance of AMT-126 in Healthy Male and Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 26, 2021

Primary Completion Date

March 26, 2022

Study Completion Date

March 26, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

AMT-126

Single or daily dosing at doses A, B, C, D, E, F; G, H, and I

DRUG

Placebo

Single or daily dosing at doses A, B, C, D, E, F; G,H, and I

OTHER

Radioactive Tablet (Part 2 Only)

Single dose in two periods in Part 2 (optional)

Trial Locations (1)

NG11 6JS

Quotient Sciences, Ruddington

Sponsors
All Listed Sponsors
lead

Applied Molecular Transport

INDUSTRY

NCT05476107 - SAD Study to Assess the Safety, Tolerability, PK, and In-Vivo Performance of AMT-126 in Healthy Male and Female Subjects | Biotech Hunter | Biotech Hunter